| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2011.548804 |
| P8608 | Fatcat ID | release_dnaglflfdbgbjb67bhuwzuvjuu |
| P698 | PubMed publication ID | 21204723 |
| P2093 | author name string | Silvia Barra | |
| Nunzia Silvestri | |||
| Crescenzo Materazzi | |||
| Giancarlo Vitagliano | |||
| Giovanni Gaeta | |||
| Vittoria Cuomo | |||
| Simona Lanero | |||
| P2860 | cites work | Development of antibody against epitope of lipoprotein(a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a). | Q54559162 |
| Testosterone decreases lipoprotein(a) in men. | Q55066488 | ||
| Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer | Q57337242 | ||
| Anabolic Androgenic Steroids and Suicide | Q58299439 | ||
| High-affinity anti-oestrogen binding site distinct from the oestrogen receptor | Q59082035 | ||
| The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. | Q51797638 | ||
| Apolipoprotein(a) yeast artificial chromosome transgenic rabbits. Lipoprotein(a) assembly with human and rabbit apolipoprotein B. | Q52190749 | ||
| High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. | Q52764830 | ||
| Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice | Q24315861 | ||
| Pharmacology of anabolic steroids | Q24650695 | ||
| Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer | Q28142158 | ||
| Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies | Q28145420 | ||
| Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial | Q28196294 | ||
| The decline of androgen levels in elderly men and its clinical and therapeutic implications | Q28251483 | ||
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity | Q28286359 | ||
| cDNA sequence of human apolipoprotein(a) is homologous to plasminogen | Q28302632 | ||
| Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q29619251 | ||
| Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force | Q30703758 | ||
| Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data | Q31150485 | ||
| Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging | Q31831299 | ||
| Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review | Q33312762 | ||
| Genetic architecture and evolution of the lipoprotein(a) trait | Q33635167 | ||
| Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications | Q33872639 | ||
| Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. | Q33896318 | ||
| Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis | Q33915460 | ||
| Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society | Q34098687 | ||
| Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study | Q34113431 | ||
| Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline | Q34119261 | ||
| Anabolic steroid abuse and dependence | Q34149477 | ||
| The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate | Q34154477 | ||
| Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. | Q34373392 | ||
| Endometrial cancer and hormone-replacement therapy in the Million Women Study | Q34415404 | ||
| Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. | Q34543818 | ||
| Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis | Q34563905 | ||
| Androgens and coronary artery disease | Q35109614 | ||
| Lipoprotein (a) concentrations in postmenopausal women taking norethisterone | Q35180738 | ||
| Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). | Q35328774 | ||
| Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma | Q35600471 | ||
| Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations | Q35603379 | ||
| Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality | Q35737842 | ||
| Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models | Q35746979 | ||
| Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male | Q35914180 | ||
| Low serum testosterone and mortality in older men. | Q36360750 | ||
| Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations | Q37122641 | ||
| Testosterone deficiency syndrome: treatment and cancer risk | Q37476208 | ||
| Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women | Q37477171 | ||
| Lipoprotein(a): from molecules to therapeutics. | Q37755937 | ||
| Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? | Q39332677 | ||
| Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. | Q39801914 | ||
| A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. | Q40672982 | ||
| Turnover of lipoprotein (a) in man. | Q40687141 | ||
| Androgens in men--uses and abuses | Q40965438 | ||
| Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells | Q41060199 | ||
| Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). | Q41126602 | ||
| Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin | Q41719517 | ||
| Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause | Q41730862 | ||
| A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine | Q42165328 | ||
| The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration | Q42600872 | ||
| Low serum testosterone and increased mortality in men with coronary heart disease | Q42853956 | ||
| Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. | Q43158726 | ||
| Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women | Q43567251 | ||
| Effect of letrozole on the lipid profile in postmenopausal women with breast cancer | Q43708436 | ||
| Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women | Q43748764 | ||
| Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies | Q43766421 | ||
| Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. | Q43813835 | ||
| Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques | Q43868646 | ||
| Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? | Q43933412 | ||
| A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women | Q43992057 | ||
| Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry | Q44028328 | ||
| Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins | Q44181135 | ||
| Genetically elevated lipoprotein(a) and increased risk of myocardial infarction | Q44238417 | ||
| Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces | Q44405157 | ||
| Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin | Q44474796 | ||
| Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer | Q44648087 | ||
| Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. | Q44655945 | ||
| Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy | Q44752125 | ||
| Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. | Q44851044 | ||
| Molecular characterization of the microsomal tamoxifen binding site | Q44919464 | ||
| The influence of 5-year therapy with tibolone on the lipid profile in postmenopausal women with mild hypercholesterolemia. | Q45007010 | ||
| Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women | Q45043374 | ||
| Estrogen plus progestin and risk of venous thrombosis | Q45092058 | ||
| Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer | Q45147044 | ||
| Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? | Q45161697 | ||
| Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. | Q45173121 | ||
| Low serum testosterone and mortality in male veterans | Q45332648 | ||
| Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause | Q46059457 | ||
| The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). | Q46427619 | ||
| The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. | Q46431843 | ||
| Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers | Q46660405 | ||
| Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. | Q46693462 | ||
| Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes | Q46724484 | ||
| Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study | Q46881122 | ||
| Molecular definition of the extreme size polymorphism in apolipoprotein(a). | Q47390927 | ||
| Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort | Q48960509 | ||
| Genetic variants associated with Lp(a) lipoprotein level and coronary disease. | Q50572117 | ||
| Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. | Q50930459 | ||
| Effect of testosterone enanthate on serum lipoproteins in man. | Q51047124 | ||
| Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. | Q51060020 | ||
| Effect of tamoxifen on serum lipid metabolism. | Q51569938 | ||
| Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. | Q51573778 | ||
| Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism. | Q51585992 | ||
| Effects of tibolone on lipoprotein(a) and HDL subfractions. | Q51592788 | ||
| Reduction of serum lipoprotein (a) by estrogen in men with prostatic cancer. | Q51598976 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipoprotein | Q28350 |
| LPA | Q18028636 | ||
| P304 | page(s) | 221-238 | |
| P577 | publication date | 2011-01-04 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Sex hormones and lipoprotein(a) concentration | |
| P478 | volume | 20 |
| Q36539756 | Lipoprotein(a) metabolism: potential sites for therapeutic targets |
| Q89884971 | Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule |
| Q38045424 | Lipoprotein(a): resurrected by genetics |
| Q39233122 | Reproductive toxicity of nanoscale graphene oxide in male mice |
Search more.